Polycystic ovary syndrome in adolescents

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 5, 2012, Pages 281-287

  Rackow, Beth W ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

adolescent; insulin resistance; polycystic ovary syndrome

Indexed keywords

INSULIN SENSITIZING AGENT;

ADOLESCENT DISEASE; ANOVULATION; BEHAVIOR CHANGE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DIET; DISEASE SEVERITY; ECHOGRAPHY; EXERCISE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC DISORDER; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SLEEP DISORDER;

ADOLESCENT; FEMALE; HUMANS; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; SLEEP DISORDERS;

EID: 84866415897     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32835669ff     Document Type: Review

References (50)

1. Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97:28-38.
2. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. pp. 377-384.
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
4. Azziz R, Carmina E, Dewailly D, et al. Task force on the phenotype of the polycystic ovary syndrome of the Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome; the complete task force report. Fertil Steril 2009; 91:456-488.
5. Avvad CK, Holeuwerger R, Silva VC, et al. Menstrual irregularity in the first postmenarchal years: an early clinical sign of polycystic ovary syndrome in adolescence. Gynecol Endocrinol 2001; 15:170-177. (Pubitemid 32640921)
6. Shayya R, Chang RJ. Reproductive endocrinology of adolescent polycystic ovary syndrome. BJOG 2010; 117:150-155.
7. Hickey M, Balen A. Menstrual disorders in adolescence: investigation and management. Hum Reprod Update 2003; 9:493-495.
8. Apter D. Endocrine and metabolic abnormalities in adolescents with a PCOSlike condition: consequences for adult reproduction. Trends Endocrinol Metab 1998; 9:58-61. (Pubitemid 28207614)
9. Wiksten-Almstromer M, Hirschberg AL, Hagenfeldt K. Prospective follow-up of menstrual disorders in adolescence and prognostic factors. Acta Obstet Gynecol Scand 2008; 87:1162-1168.
10. Slayden SM, Moran C, Sams WM Jr, et al. Hyperandrogenemia in patients presenting with acne. Fertil Steril 2001; 75:889-892. (Pubitemid 32401665)
11. Roe AH, Dokras A. The diagnosis of polycystic ovary syndrome in adolescents. Rev Obstet Gynecol 2011; 4:45-51.
12. Jeffrey CR, Coffler MS. Polycystic ovary syndrome: early detection in the adolescent. Clin Obstet Gynecol 2007; 50:178-187. (Pubitemid 46279861)
13. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010; 203:201-205.
14. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307:483-490.
15. Van Hooff MH, Voorhorst FJ, Kaptein MB, et al. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod 2004; 19:383-392. (Pubitemid 38220012)
16. Balen AH, Laven JS, Tan SL, et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9:505-514. (Pubitemid 38072143)
17. Mortensen M, Rosenfield RL, Littlejohn E. Functional significance of polycystic-size ovaries in healthy adolescents. J Clin Endocrinol Metab 2006; 91:3786-3790. (Pubitemid 44536844)
18. Johnstone EB, Rosen MP, Neril R, et al. The polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab 2010; 95:4965-4972.
19. Hickey M, Doherty DA, Atkinson H, et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. Hum Reprod 2011; 26:1469-1477.
20. Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome-a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92:4546-4556. (Pubitemid 350223423)
21. Teede HJ, Hutchinson S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes and cardiovascular disease risk in women with PCOS. Endocrine 2006; 30:45-53. (Pubitemid 46020329)
22. Hart R. Polycystic ovarian syndrome-prognosis and treatment outcomes. Curr Opin Obstet Gynecol 2007; 19:529-535. (Pubitemid 350147813)
23. Hart R, Doherty DA, Mori T, et al. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril 2011; 95:2347-2353.
24. Ford ES, Li C. Defining the metabolic syndrome in children and adolescents: will the real definition please stand up? J Pediatr 2008; 152:160-164.
25. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91:492-497. (Pubitemid 43236914)
26. Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol 2010; 162:1093-1099.
27. Fogel RB, Malhotra A, Pillar G, et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86:1175-1180. (Pubitemid 32323001)
28. Vgontzas AN, Legro RS, Bixler EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001; 86:517-520. (Pubitemid 32207453)
29. Tasali E, Van Cauter E, Ehrmann DA. Polycystic ovary syndrome and obstructive sleep apnea. Sleep Med Clin 2008; 3:37-46.
30. De Sousa G, Schlü ter B, Menke T, et al. A comparison of polysomnographic variables between adolescents with polycystic ovarian syndrome with and without the metabolic syndrome. Metab Syndr Relat Disord 2011; 9:191-196.
31. De Sousa G, Schlü ter B, Buschatz D, et al. A comparison of polysomnographic variables between obese adolescents with polycystic ovarian syndrome and healthy, normal-weight and obese adolescents. Sleep Breath 2010; 14:33-38.
32. Nandalike K, Strauss T, Agarwal C, et al. Screening for sleep-disordered breathing and excessive daytime sleepiness in adolescent girls with polycystic ovarian syndrome. J Pediatr 2011; 159:591-596.
33. Freemark M. Management of adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96:3354-3356.
34. Geller DH, Pacaud D, Gordon CM, et al. State of the art review: Emerging therapies: The use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol 2011; 9. http://www.ijpeonline.com/content/2011/1/9.
35. Moran LJ, Hetchinson SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011; 7:CD007506.
36. Moran LJ, Noakes M, Clifton PM, et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:812-819. (Pubitemid 36207827)
37. Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebocontrolled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004; 82:421-429. (Pubitemid 39092044)
38. Stamets K, Taylor DS, Kunselman A, et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004; 81:630-637. (Pubitemid 38376121)
39. Lass N, Kleber M, Winkel K, et al. Effect of lifestyle intervention on features of polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent girls. J Clin Endocrinol Metab 2011; 96:3533-3540.
40. Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2011; 24:161-165.
41. Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 2003; 80:255-258. (Pubitemid 36959775)
42. Arslanian SA, Lewy V, Danadian K, et al. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002; 87:1555-1559. (Pubitemid 34615238)
43. Glueck CJ, Wang P, Fontaine R, et al. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001; 29:160-169. (Pubitemid 32755792)
44. De Leo V, Musacchio MC, Morgante G, et al. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod 2006; 21:2252-2256. (Pubitemid 44530597)
45. Glueck CJ, Aregawi D, Winiarska M, et al. Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 19:831-842. (Pubitemid 44083540)
46. Hoeger K, Davidson K, Kochman L, et al. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008; 93:4299-4306. (Pubitemid 352789525)
47. Bridger T, MacDonald S, Baltzer F, et al. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2006; 160:241-246. (Pubitemid 43374356)
48. Ibanez L, Valls C, Potau N, et al. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenemia, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000; 85:3526-3530.
49. Ibanez L, de Zegher F. Low dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women. Hum Reprod Update 2006; 12:243-252.
50. Ibanez L, Lopez-Bermejo A, Diaz M, et al. Early metformin therapy (ages 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab 2011; 96:E1262-E1267.